Brazil Cancer Immunotherapy Market Size & Outlook
Brazil cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Brazil cancer immunotherapy market highlights
- The Brazil cancer immunotherapy market generated a revenue of USD 1,939.3 million in 2023 and is expected to reach USD 3,210.0 million by 2030.
- The Brazil market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 1,939.3 million |
| Market revenue in 2030 | USD 3,210.0 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Brazil accounted for 1.5% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 1,016.6 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.55% in 2023. Horizon Databook has segmented the Brazil cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer remains the second leading cause of mortality in Brazil as of 2019. Immunotherapy has revolutionized the cancer treatment paradigm in Brazil, where the disease burden continues to grow at a steady pace.
Although the availability and accessibility of cost-effective oncologic immunotherapeutic drugs are likely to drive the market growth, factors such as gaps in the Brazilian healthcare system, unmet healthcare needs, and financial constraints may restrain market growth. Combinatorial immunotherapeutic approaches are gaining rapid momentum in the Brazilian cancer market.
In order to combat the high price of immunooncology drugs, some of the initiatives implemented in Brazil include CONITEC, petitioned by the Brazilian Society of Clinical Oncology, to determine the aptness of a pharmaceutical agent into the public healthcare system, leading to increased drug accessibility.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil cancer immunotherapy market size, by product, 2018-2030 (US$M)
Brazil Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
